Core Points - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2] - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application [2] - Investors who suffered losses during the specified period have until October 14, 2025, to request to be appointed as lead plaintiff, with no out-of-pocket costs to participate [3] Company Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on October 14, 2025 [1]. Group 1: Class Action Details - Investors who bought Unicycive securities between March 29, 2024, and June 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lead plaintiff must file a motion with the Court by October 14, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Unicycive's management made false or misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application for oxylanthanum carbunate [5]. - It is claimed that these misrepresentations led to investor damages when the true information became public [5].

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - It is alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [2]. - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3]. - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors off a class action on behalf of investors that bought securities between March 29, 2024 and June 27, 2025, inclusive (the “Class Period”). Unicycive investors have until October 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 29, 2024, to June 27, 2025 [1]. - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its new drug application for oxylanthanum carbonate [1]. - As a result of these alleged misstatements, the defendants' public statements were deemed materially false and misleading throughout the relevant time [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of UNCY during the class period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for October 14, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 14, 2025 [4]. Group 1: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA [6]. - Specific deficiencies in cGMP compliance were identified at a third-party manufacturing vendor, which were not disclosed prior to the FDA's findings [7]. Group 2: Stock Price Impact - Following the announcement of deficiencies on June 10, 2025, Unicycive's stock price fell by $3.68 per share, a decrease of 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Legal Process and Participation - The lead plaintiff in the class action is the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the class [9]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [9].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit alleges that Unicycive's management assured investors of the company's ability to satisfy FDA requirements, which was later revealed to be overstated [8] - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party vendor, leading to a stock price drop of over 40% [8] - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4] - The law firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - Investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, are encouraged to contact the firm to discuss their legal rights [1][4]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [7]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [8].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for oxylanthanum carbonate [7] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [7] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [7] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [7] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [7] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price decline of almost 30%, closing at $4.77 per share [7] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4][8] - The law firm represents individual and institutional investors in complex litigation across the United States [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, encouraging affected investors to discuss their legal options [1][3]. Group 1: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its OLC NDA [3]. - Specific claims include overstated readiness to meet FDA compliance and misrepresentation of the NDA's regulatory prospects, leading to materially false public statements [3]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, which disclosed deficiencies in cGMP compliance at a third-party vendor, Unicycive's stock price fell by $3.68, or 40.89%, closing at $5.32 per share [4]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same cGMP deficiencies, the stock price dropped by $2.03, or 29.85%, closing at $4.77 per share [5]. Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Unicycive is October 14, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member, with no impact on their ability to share in any recovery [6].